Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates

By Shanthi Rexaline of Benzinga.com
Sunday, November 22, 2020 8:18 AM EDT

Liquidia Technologies Inc (LQDA) awaits FDA word on its NDA for LIQ861, an investigational, inhaled dry powder formulation of Treprostinil for the treatment of pulmonary arterial hypertension. (Tuesday)

Revance Therapeutics Inc's (RVNC) regulatory application for Daxi in the treatment of moderate to severe glabellar, or frown, lines has a FDA decision date of Nov. 25. (Wednesday)

The FDA is also expected to announce its verdict on Rhythm Pharmaceuticals Inc's (RYTM) new drug application for setmelanotide in genetically-induced obesity. (Friday)

Earnings

  • Twist Bioscience Corp (TWST) (Monday, before the market open)
  • Arrowhead Pharmaceuticals Inc (ARWR)(Monday, after the close)
  • Enanta Pharmaceuticals Inc (ENTA) (Monday, after the close)
  • Medtronic PLC (MDT) (Tuesday, before the market open)
  • China Biologic Products Holdings Inc (CBPO)(Tuesday, after the close)

Other Events

Moderna could announce final Phase 3 data for its mRNA vaccine candidate mRNA-1273, and then apply for emergency use authorization.

IPO Quiet Period Expiry

  • Biodesix Inc 
  • Galecto, Inc.  
  • Atea Pharmaceuticals, Inc. 
  • SQZ Biotechnologies Co 
1 2
View single page >> |

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.